nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—FKBP1A—esophageal cancer	0.68	0.931	CbGaD
Tacrolimus—ABCB1—esophageal cancer	0.0501	0.0686	CbGaD
Tacrolimus—ABCA5—bronchus—esophageal cancer	0.00277	0.0746	CbGeAlD
Tacrolimus—ABCA5—trachea—esophageal cancer	0.00248	0.067	CbGeAlD
Tacrolimus—Pimecrolimus—FKBP1A—esophageal cancer	0.0024	0.297	CrCbGaD
Tacrolimus—Everolimus—FKBP1A—esophageal cancer	0.0024	0.297	CrCbGaD
Tacrolimus—MTOR—neck—esophageal cancer	0.00206	0.0556	CbGeAlD
Tacrolimus—PPP3CA—bronchus—esophageal cancer	0.00187	0.0504	CbGeAlD
Tacrolimus—FKBP1A—neck—esophageal cancer	0.00185	0.05	CbGeAlD
Tacrolimus—PPP3CA—smooth muscle tissue—esophageal cancer	0.00183	0.0493	CbGeAlD
Tacrolimus—ABCA5—lung—esophageal cancer	0.00178	0.0481	CbGeAlD
Tacrolimus—PPP3CA—trachea—esophageal cancer	0.00168	0.0453	CbGeAlD
Tacrolimus—Temsirolimus—FKBP1A—esophageal cancer	0.00162	0.201	CrCbGaD
Tacrolimus—PPP3CA—digestive system—esophageal cancer	0.00144	0.0389	CbGeAlD
Tacrolimus—Sirolimus—FKBP1A—esophageal cancer	0.00143	0.177	CrCbGaD
Tacrolimus—MTOR—epithelium—esophageal cancer	0.0014	0.0378	CbGeAlD
Tacrolimus—MTOR—smooth muscle tissue—esophageal cancer	0.00135	0.0364	CbGeAlD
Tacrolimus—FKBP1A—epithelium—esophageal cancer	0.00126	0.034	CbGeAlD
Tacrolimus—FKBP1A—bronchus—esophageal cancer	0.00124	0.0335	CbGeAlD
Tacrolimus—ABCA5—lymph node—esophageal cancer	0.00122	0.0329	CbGeAlD
Tacrolimus—FKBP1A—smooth muscle tissue—esophageal cancer	0.00121	0.0328	CbGeAlD
Tacrolimus—PPP3CA—lung—esophageal cancer	0.00121	0.0325	CbGeAlD
Tacrolimus—FKBP1A—trachea—esophageal cancer	0.00111	0.0301	CbGeAlD
Tacrolimus—MTOR—digestive system—esophageal cancer	0.00107	0.0288	CbGeAlD
Tacrolimus—FKBP1A—digestive system—esophageal cancer	0.000959	0.0259	CbGeAlD
Tacrolimus—MTOR—lung—esophageal cancer	0.00089	0.024	CbGeAlD
Tacrolimus—PPP3CA—lymph node—esophageal cancer	0.000824	0.0222	CbGeAlD
Tacrolimus—FKBP1A—lung—esophageal cancer	0.000801	0.0216	CbGeAlD
Tacrolimus—ORM1—lung—esophageal cancer	0.000627	0.0169	CbGeAlD
Tacrolimus—MTOR—lymph node—esophageal cancer	0.000609	0.0164	CbGeAlD
Tacrolimus—FKBP1A—lymph node—esophageal cancer	0.000548	0.0148	CbGeAlD
Tacrolimus—ORM1—lymph node—esophageal cancer	0.000429	0.0116	CbGeAlD
Tacrolimus—CYP3A5—digestive system—esophageal cancer	0.000418	0.0113	CbGeAlD
Tacrolimus—ALB—lymph node—esophageal cancer	0.000376	0.0101	CbGeAlD
Tacrolimus—CYP3A5—lung—esophageal cancer	0.000349	0.00941	CbGeAlD
Tacrolimus—CYP3A4—digestive system—esophageal cancer	0.000313	0.00845	CbGeAlD
Tacrolimus—ABCB1—epithelium—esophageal cancer	0.000292	0.00787	CbGeAlD
Tacrolimus—ABCB1—trachea—esophageal cancer	0.000258	0.00696	CbGeAlD
Tacrolimus—ABCB1—digestive system—esophageal cancer	0.000222	0.00598	CbGeAlD
Tacrolimus—ABCB1—lung—esophageal cancer	0.000185	0.005	CbGeAlD
Tacrolimus—Angina pectoris—Capecitabine—esophageal cancer	0.000144	0.00113	CcSEcCtD
Tacrolimus—Sweating increased—Capecitabine—esophageal cancer	0.000144	0.00113	CcSEcCtD
Tacrolimus—Arrhythmia—Cisplatin—esophageal cancer	0.000144	0.00112	CcSEcCtD
Tacrolimus—Bronchitis—Capecitabine—esophageal cancer	0.000142	0.00111	CcSEcCtD
Tacrolimus—Alopecia—Cisplatin—esophageal cancer	0.000142	0.00111	CcSEcCtD
Tacrolimus—Hepatic failure—Methotrexate—esophageal cancer	0.000142	0.00111	CcSEcCtD
Tacrolimus—Pancytopenia—Capecitabine—esophageal cancer	0.000141	0.0011	CcSEcCtD
Tacrolimus—Malnutrition—Cisplatin—esophageal cancer	0.00014	0.0011	CcSEcCtD
Tacrolimus—Erythema—Cisplatin—esophageal cancer	0.00014	0.0011	CcSEcCtD
Tacrolimus—Dysuria—Capecitabine—esophageal cancer	0.000138	0.00108	CcSEcCtD
Tacrolimus—Neutropenia—Capecitabine—esophageal cancer	0.000138	0.00108	CcSEcCtD
Tacrolimus—Renal failure acute—Methotrexate—esophageal cancer	0.000138	0.00108	CcSEcCtD
Tacrolimus—Flatulence—Cisplatin—esophageal cancer	0.000138	0.00108	CcSEcCtD
Tacrolimus—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000135	0.00106	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000135	0.00106	CcSEcCtD
Tacrolimus—Weight increased—Capecitabine—esophageal cancer	0.000135	0.00105	CcSEcCtD
Tacrolimus—Muscle spasms—Cisplatin—esophageal cancer	0.000134	0.00105	CcSEcCtD
Tacrolimus—Weight decreased—Capecitabine—esophageal cancer	0.000134	0.00105	CcSEcCtD
Tacrolimus—Hyperglycaemia—Capecitabine—esophageal cancer	0.000133	0.00105	CcSEcCtD
Tacrolimus—Pneumonia—Capecitabine—esophageal cancer	0.000133	0.00104	CcSEcCtD
Tacrolimus—Infestation—Capecitabine—esophageal cancer	0.000132	0.00103	CcSEcCtD
Tacrolimus—Infestation NOS—Capecitabine—esophageal cancer	0.000132	0.00103	CcSEcCtD
Tacrolimus—Vision blurred—Cisplatin—esophageal cancer	0.000132	0.00103	CcSEcCtD
Tacrolimus—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000132	0.00103	CcSEcCtD
Tacrolimus—Depression—Capecitabine—esophageal cancer	0.000132	0.00103	CcSEcCtD
Tacrolimus—Tremor—Cisplatin—esophageal cancer	0.000131	0.00103	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000131	0.00102	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00013	0.00102	CcSEcCtD
Tacrolimus—Ill-defined disorder—Cisplatin—esophageal cancer	0.00013	0.00102	CcSEcCtD
Tacrolimus—Renal failure—Capecitabine—esophageal cancer	0.00013	0.00102	CcSEcCtD
Tacrolimus—Myocardial infarction—Capecitabine—esophageal cancer	0.000129	0.00101	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000129	0.00101	CcSEcCtD
Tacrolimus—Anaemia—Cisplatin—esophageal cancer	0.000129	0.00101	CcSEcCtD
Tacrolimus—Stomatitis—Capecitabine—esophageal cancer	0.000129	0.00101	CcSEcCtD
Tacrolimus—Jaundice—Capecitabine—esophageal cancer	0.000129	0.00101	CcSEcCtD
Tacrolimus—Urinary tract infection—Capecitabine—esophageal cancer	0.000128	0.001	CcSEcCtD
Tacrolimus—Conjunctivitis—Capecitabine—esophageal cancer	0.000128	0.001	CcSEcCtD
Tacrolimus—Osteoarthritis—Methotrexate—esophageal cancer	0.000127	0.000998	CcSEcCtD
Tacrolimus—ABCB1—lymph node—esophageal cancer	0.000127	0.00342	CbGeAlD
Tacrolimus—Malaise—Cisplatin—esophageal cancer	0.000126	0.000988	CcSEcCtD
Tacrolimus—Haematuria—Capecitabine—esophageal cancer	0.000126	0.000985	CcSEcCtD
Tacrolimus—Leukopenia—Cisplatin—esophageal cancer	0.000125	0.00098	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000125	0.000977	CcSEcCtD
Tacrolimus—Epistaxis—Capecitabine—esophageal cancer	0.000124	0.000974	CcSEcCtD
Tacrolimus—Agranulocytosis—Capecitabine—esophageal cancer	0.000123	0.000964	CcSEcCtD
Tacrolimus—Convulsion—Cisplatin—esophageal cancer	0.000121	0.000949	CcSEcCtD
Tacrolimus—Mood swings—Methotrexate—esophageal cancer	0.000121	0.000945	CcSEcCtD
Tacrolimus—Bradycardia—Capecitabine—esophageal cancer	0.000121	0.000944	CcSEcCtD
Tacrolimus—Temsirolimus—ABCB1—esophageal cancer	0.000119	0.0148	CrCbGaD
Tacrolimus—Myalgia—Cisplatin—esophageal cancer	0.000119	0.000932	CcSEcCtD
Tacrolimus—Haemoglobin—Capecitabine—esophageal cancer	0.000119	0.000932	CcSEcCtD
Tacrolimus—Rhinitis—Capecitabine—esophageal cancer	0.000119	0.00093	CcSEcCtD
Tacrolimus—Anxiety—Cisplatin—esophageal cancer	0.000119	0.000929	CcSEcCtD
Tacrolimus—Haemorrhage—Capecitabine—esophageal cancer	0.000118	0.000927	CcSEcCtD
Tacrolimus—Hepatitis—Capecitabine—esophageal cancer	0.000118	0.000927	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000118	0.000926	CcSEcCtD
Tacrolimus—Hypoaesthesia—Capecitabine—esophageal cancer	0.000118	0.000923	CcSEcCtD
Tacrolimus—Liver function test abnormal—Methotrexate—esophageal cancer	0.000118	0.000921	CcSEcCtD
Tacrolimus—Discomfort—Cisplatin—esophageal cancer	0.000118	0.000921	CcSEcCtD
Tacrolimus—Pharyngitis—Capecitabine—esophageal cancer	0.000118	0.00092	CcSEcCtD
Tacrolimus—Urinary tract disorder—Capecitabine—esophageal cancer	0.000117	0.000916	CcSEcCtD
Tacrolimus—Oedema peripheral—Capecitabine—esophageal cancer	0.000117	0.000914	CcSEcCtD
Tacrolimus—Connective tissue disorder—Capecitabine—esophageal cancer	0.000116	0.000911	CcSEcCtD
Tacrolimus—Urethral disorder—Capecitabine—esophageal cancer	0.000116	0.000909	CcSEcCtD
Tacrolimus—Breast disorder—Methotrexate—esophageal cancer	0.000115	0.000902	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000115	0.000899	CcSEcCtD
Tacrolimus—Oedema—Cisplatin—esophageal cancer	0.000114	0.000894	CcSEcCtD
Tacrolimus—Anaphylactic shock—Cisplatin—esophageal cancer	0.000114	0.000894	CcSEcCtD
Tacrolimus—Visual impairment—Capecitabine—esophageal cancer	0.000114	0.000894	CcSEcCtD
Tacrolimus—Infection—Cisplatin—esophageal cancer	0.000113	0.000888	CcSEcCtD
Tacrolimus—Erythema multiforme—Capecitabine—esophageal cancer	0.000112	0.000877	CcSEcCtD
Tacrolimus—Nervous system disorder—Cisplatin—esophageal cancer	0.000112	0.000877	CcSEcCtD
Tacrolimus—Thrombocytopenia—Cisplatin—esophageal cancer	0.000112	0.000875	CcSEcCtD
Tacrolimus—Tachycardia—Cisplatin—esophageal cancer	0.000111	0.000872	CcSEcCtD
Tacrolimus—Skin disorder—Cisplatin—esophageal cancer	0.000111	0.000868	CcSEcCtD
Tacrolimus—Eye disorder—Capecitabine—esophageal cancer	0.000111	0.000867	CcSEcCtD
Tacrolimus—Tinnitus—Capecitabine—esophageal cancer	0.00011	0.000865	CcSEcCtD
Tacrolimus—Hyperhidrosis—Cisplatin—esophageal cancer	0.00011	0.000864	CcSEcCtD
Tacrolimus—Asthma—Methotrexate—esophageal cancer	0.00011	0.000863	CcSEcCtD
Tacrolimus—Cardiac disorder—Capecitabine—esophageal cancer	0.00011	0.000861	CcSEcCtD
Tacrolimus—Flushing—Capecitabine—esophageal cancer	0.00011	0.000861	CcSEcCtD
Tacrolimus—Anorexia—Cisplatin—esophageal cancer	0.000109	0.000852	CcSEcCtD
Tacrolimus—Pancreatitis—Methotrexate—esophageal cancer	0.000108	0.000846	CcSEcCtD
Tacrolimus—Angiopathy—Capecitabine—esophageal cancer	0.000107	0.000841	CcSEcCtD
Tacrolimus—Immune system disorder—Capecitabine—esophageal cancer	0.000107	0.000838	CcSEcCtD
Tacrolimus—Mediastinal disorder—Capecitabine—esophageal cancer	0.000107	0.000836	CcSEcCtD
Tacrolimus—Hypotension—Cisplatin—esophageal cancer	0.000107	0.000835	CcSEcCtD
Tacrolimus—Chills—Capecitabine—esophageal cancer	0.000106	0.000832	CcSEcCtD
Tacrolimus—Arrhythmia—Capecitabine—esophageal cancer	0.000106	0.000828	CcSEcCtD
Tacrolimus—Sirolimus—ABCB1—esophageal cancer	0.000105	0.013	CrCbGaD
Tacrolimus—Alopecia—Capecitabine—esophageal cancer	0.000105	0.000819	CcSEcCtD
Tacrolimus—Pancytopenia—Methotrexate—esophageal cancer	0.000105	0.000819	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000104	0.000814	CcSEcCtD
Tacrolimus—Mental disorder—Capecitabine—esophageal cancer	0.000104	0.000812	CcSEcCtD
Tacrolimus—Erythema—Capecitabine—esophageal cancer	0.000103	0.000807	CcSEcCtD
Tacrolimus—Malnutrition—Capecitabine—esophageal cancer	0.000103	0.000807	CcSEcCtD
Tacrolimus—Dysuria—Methotrexate—esophageal cancer	0.000103	0.000807	CcSEcCtD
Tacrolimus—Neutropenia—Methotrexate—esophageal cancer	0.000103	0.000807	CcSEcCtD
Tacrolimus—Paraesthesia—Cisplatin—esophageal cancer	0.000102	0.000803	CcSEcCtD
Tacrolimus—Dyspnoea—Cisplatin—esophageal cancer	0.000102	0.000797	CcSEcCtD
Tacrolimus—Flatulence—Capecitabine—esophageal cancer	0.000102	0.000796	CcSEcCtD
Tacrolimus—Dysgeusia—Capecitabine—esophageal cancer	0.000101	0.000791	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000101	0.000787	CcSEcCtD
Tacrolimus—Back pain—Capecitabine—esophageal cancer	9.97e-05	0.000781	CcSEcCtD
Tacrolimus—Decreased appetite—Cisplatin—esophageal cancer	9.92e-05	0.000777	CcSEcCtD
Tacrolimus—Muscle spasms—Capecitabine—esophageal cancer	9.91e-05	0.000776	CcSEcCtD
Tacrolimus—Pneumonia—Methotrexate—esophageal cancer	9.88e-05	0.000774	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Cisplatin—esophageal cancer	9.85e-05	0.000772	CcSEcCtD
Tacrolimus—Infestation—Methotrexate—esophageal cancer	9.82e-05	0.000769	CcSEcCtD
Tacrolimus—Infestation NOS—Methotrexate—esophageal cancer	9.82e-05	0.000769	CcSEcCtD
Tacrolimus—Depression—Methotrexate—esophageal cancer	9.79e-05	0.000767	CcSEcCtD
Tacrolimus—Pain—Cisplatin—esophageal cancer	9.76e-05	0.000764	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	9.74e-05	0.000762	CcSEcCtD
Tacrolimus—Vision blurred—Capecitabine—esophageal cancer	9.72e-05	0.000761	CcSEcCtD
Tacrolimus—Tremor—Capecitabine—esophageal cancer	9.66e-05	0.000756	CcSEcCtD
Tacrolimus—Renal failure—Methotrexate—esophageal cancer	9.65e-05	0.000756	CcSEcCtD
Tacrolimus—Stomatitis—Methotrexate—esophageal cancer	9.57e-05	0.00075	CcSEcCtD
Tacrolimus—Ill-defined disorder—Capecitabine—esophageal cancer	9.57e-05	0.000749	CcSEcCtD
Tacrolimus—Conjunctivitis—Methotrexate—esophageal cancer	9.55e-05	0.000748	CcSEcCtD
Tacrolimus—Anaemia—Capecitabine—esophageal cancer	9.53e-05	0.000746	CcSEcCtD
Tacrolimus—Sweating—Methotrexate—esophageal cancer	9.41e-05	0.000737	CcSEcCtD
Tacrolimus—Feeling abnormal—Cisplatin—esophageal cancer	9.41e-05	0.000737	CcSEcCtD
Tacrolimus—Haematuria—Methotrexate—esophageal cancer	9.36e-05	0.000733	CcSEcCtD
Tacrolimus—Malaise—Capecitabine—esophageal cancer	9.3e-05	0.000728	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Methotrexate—esophageal cancer	9.29e-05	0.000727	CcSEcCtD
Tacrolimus—Epistaxis—Methotrexate—esophageal cancer	9.26e-05	0.000725	CcSEcCtD
Tacrolimus—Vertigo—Capecitabine—esophageal cancer	9.26e-05	0.000725	CcSEcCtD
Tacrolimus—Syncope—Capecitabine—esophageal cancer	9.25e-05	0.000724	CcSEcCtD
Tacrolimus—Leukopenia—Capecitabine—esophageal cancer	9.23e-05	0.000723	CcSEcCtD
Tacrolimus—Agranulocytosis—Methotrexate—esophageal cancer	9.16e-05	0.000718	CcSEcCtD
Tacrolimus—Palpitations—Capecitabine—esophageal cancer	9.11e-05	0.000713	CcSEcCtD
Tacrolimus—Loss of consciousness—Capecitabine—esophageal cancer	9.06e-05	0.00071	CcSEcCtD
Tacrolimus—Body temperature increased—Cisplatin—esophageal cancer	9.02e-05	0.000707	CcSEcCtD
Tacrolimus—Cough—Capecitabine—esophageal cancer	9e-05	0.000704	CcSEcCtD
Tacrolimus—Hypertension—Capecitabine—esophageal cancer	8.9e-05	0.000697	CcSEcCtD
Tacrolimus—Haemoglobin—Methotrexate—esophageal cancer	8.86e-05	0.000694	CcSEcCtD
Tacrolimus—Haemorrhage—Methotrexate—esophageal cancer	8.82e-05	0.00069	CcSEcCtD
Tacrolimus—Hepatitis—Methotrexate—esophageal cancer	8.82e-05	0.00069	CcSEcCtD
Tacrolimus—Myalgia—Capecitabine—esophageal cancer	8.78e-05	0.000687	CcSEcCtD
Tacrolimus—Arthralgia—Capecitabine—esophageal cancer	8.78e-05	0.000687	CcSEcCtD
Tacrolimus—Chest pain—Capecitabine—esophageal cancer	8.78e-05	0.000687	CcSEcCtD
Tacrolimus—Pharyngitis—Methotrexate—esophageal cancer	8.75e-05	0.000685	CcSEcCtD
Tacrolimus—Anxiety—Capecitabine—esophageal cancer	8.75e-05	0.000685	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	8.72e-05	0.000683	CcSEcCtD
Tacrolimus—Urinary tract disorder—Methotrexate—esophageal cancer	8.71e-05	0.000682	CcSEcCtD
Tacrolimus—Discomfort—Capecitabine—esophageal cancer	8.67e-05	0.000679	CcSEcCtD
Tacrolimus—Urethral disorder—Methotrexate—esophageal cancer	8.64e-05	0.000677	CcSEcCtD
Tacrolimus—Dry mouth—Capecitabine—esophageal cancer	8.58e-05	0.000672	CcSEcCtD
Tacrolimus—Visual impairment—Methotrexate—esophageal cancer	8.5e-05	0.000665	CcSEcCtD
Tacrolimus—Confusional state—Capecitabine—esophageal cancer	8.48e-05	0.000664	CcSEcCtD
Tacrolimus—Oedema—Capecitabine—esophageal cancer	8.41e-05	0.000659	CcSEcCtD
Tacrolimus—Hypersensitivity—Cisplatin—esophageal cancer	8.41e-05	0.000659	CcSEcCtD
Tacrolimus—Infection—Capecitabine—esophageal cancer	8.36e-05	0.000655	CcSEcCtD
Tacrolimus—Erythema multiforme—Methotrexate—esophageal cancer	8.34e-05	0.000653	CcSEcCtD
Tacrolimus—Shock—Capecitabine—esophageal cancer	8.28e-05	0.000648	CcSEcCtD
Tacrolimus—Nervous system disorder—Capecitabine—esophageal cancer	8.25e-05	0.000646	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—esophageal cancer	8.24e-05	0.000645	CcSEcCtD
Tacrolimus—Thrombocytopenia—Capecitabine—esophageal cancer	8.24e-05	0.000645	CcSEcCtD
Tacrolimus—Tinnitus—Methotrexate—esophageal cancer	8.22e-05	0.000644	CcSEcCtD
Tacrolimus—Tachycardia—Capecitabine—esophageal cancer	8.21e-05	0.000643	CcSEcCtD
Tacrolimus—Asthenia—Cisplatin—esophageal cancer	8.19e-05	0.000641	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—esophageal cancer	8.18e-05	0.000641	CcSEcCtD
Tacrolimus—Skin disorder—Capecitabine—esophageal cancer	8.17e-05	0.00064	CcSEcCtD
Tacrolimus—Hyperhidrosis—Capecitabine—esophageal cancer	8.13e-05	0.000637	CcSEcCtD
Tacrolimus—Anorexia—Capecitabine—esophageal cancer	8.02e-05	0.000628	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—esophageal cancer	8e-05	0.000626	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—esophageal cancer	7.96e-05	0.000624	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—esophageal cancer	7.95e-05	0.000622	CcSEcCtD
Tacrolimus—Chills—Methotrexate—esophageal cancer	7.91e-05	0.000619	CcSEcCtD
Tacrolimus—Hypotension—Capecitabine—esophageal cancer	7.86e-05	0.000616	CcSEcCtD
Tacrolimus—Diarrhoea—Cisplatin—esophageal cancer	7.81e-05	0.000612	CcSEcCtD
Tacrolimus—Alopecia—Methotrexate—esophageal cancer	7.79e-05	0.00061	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—esophageal cancer	7.72e-05	0.000605	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—esophageal cancer	7.67e-05	0.000601	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—esophageal cancer	7.67e-05	0.000601	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Capecitabine—esophageal cancer	7.67e-05	0.0006	CcSEcCtD
Tacrolimus—Insomnia—Capecitabine—esophageal cancer	7.61e-05	0.000596	CcSEcCtD
Tacrolimus—Paraesthesia—Capecitabine—esophageal cancer	7.56e-05	0.000592	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—esophageal cancer	7.52e-05	0.000589	CcSEcCtD
Tacrolimus—Dyspnoea—Capecitabine—esophageal cancer	7.5e-05	0.000587	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—esophageal cancer	7.42e-05	0.000581	CcSEcCtD
Tacrolimus—Dyspepsia—Capecitabine—esophageal cancer	7.41e-05	0.00058	CcSEcCtD
Tacrolimus—Decreased appetite—Capecitabine—esophageal cancer	7.31e-05	0.000573	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Capecitabine—esophageal cancer	7.26e-05	0.000569	CcSEcCtD
Tacrolimus—Vomiting—Cisplatin—esophageal cancer	7.26e-05	0.000568	CcSEcCtD
Tacrolimus—Fatigue—Capecitabine—esophageal cancer	7.25e-05	0.000568	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—esophageal cancer	7.23e-05	0.000566	CcSEcCtD
Tacrolimus—Rash—Cisplatin—esophageal cancer	7.2e-05	0.000564	CcSEcCtD
Tacrolimus—Constipation—Capecitabine—esophageal cancer	7.2e-05	0.000563	CcSEcCtD
Tacrolimus—Pain—Capecitabine—esophageal cancer	7.2e-05	0.000563	CcSEcCtD
Tacrolimus—Dermatitis—Cisplatin—esophageal cancer	7.19e-05	0.000563	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—esophageal cancer	7.12e-05	0.000558	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—esophageal cancer	7.09e-05	0.000555	CcSEcCtD
Tacrolimus—Feeling abnormal—Capecitabine—esophageal cancer	6.93e-05	0.000543	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—esophageal cancer	6.92e-05	0.000542	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—esophageal cancer	6.9e-05	0.00054	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Capecitabine—esophageal cancer	6.88e-05	0.000539	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—esophageal cancer	6.87e-05	0.000538	CcSEcCtD
Tacrolimus—Nausea—Cisplatin—esophageal cancer	6.78e-05	0.000531	CcSEcCtD
Tacrolimus—Cough—Methotrexate—esophageal cancer	6.7e-05	0.000524	CcSEcCtD
Tacrolimus—Urticaria—Capecitabine—esophageal cancer	6.68e-05	0.000523	CcSEcCtD
Tacrolimus—Body temperature increased—Capecitabine—esophageal cancer	6.65e-05	0.000521	CcSEcCtD
Tacrolimus—Abdominal pain—Capecitabine—esophageal cancer	6.65e-05	0.000521	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—esophageal cancer	6.65e-05	0.000521	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—esophageal cancer	6.53e-05	0.000512	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—esophageal cancer	6.53e-05	0.000512	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—esophageal cancer	6.53e-05	0.000512	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	6.49e-05	0.000508	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—esophageal cancer	6.46e-05	0.000506	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—esophageal cancer	6.32e-05	0.000495	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—esophageal cancer	6.26e-05	0.00049	CcSEcCtD
Tacrolimus—Infection—Methotrexate—esophageal cancer	6.22e-05	0.000487	CcSEcCtD
Tacrolimus—Hypersensitivity—Capecitabine—esophageal cancer	6.2e-05	0.000485	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—esophageal cancer	6.14e-05	0.000481	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—esophageal cancer	6.13e-05	0.00048	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—esophageal cancer	6.08e-05	0.000476	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—esophageal cancer	6.06e-05	0.000474	CcSEcCtD
Tacrolimus—Asthenia—Capecitabine—esophageal cancer	6.04e-05	0.000473	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—esophageal cancer	5.97e-05	0.000468	CcSEcCtD
Tacrolimus—Pruritus—Capecitabine—esophageal cancer	5.95e-05	0.000466	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—esophageal cancer	5.85e-05	0.000458	CcSEcCtD
Tacrolimus—Diarrhoea—Capecitabine—esophageal cancer	5.76e-05	0.000451	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—esophageal cancer	5.71e-05	0.000447	CcSEcCtD
Tacrolimus—Insomnia—Methotrexate—esophageal cancer	5.67e-05	0.000444	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—esophageal cancer	5.62e-05	0.00044	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—esophageal cancer	5.58e-05	0.000437	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—esophageal cancer	5.57e-05	0.000436	CcSEcCtD
Tacrolimus—Dizziness—Capecitabine—esophageal cancer	5.56e-05	0.000436	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—esophageal cancer	5.51e-05	0.000432	CcSEcCtD
Tacrolimus—Decreased appetite—Methotrexate—esophageal cancer	5.44e-05	0.000426	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—esophageal cancer	5.41e-05	0.000423	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—esophageal cancer	5.4e-05	0.000423	CcSEcCtD
Tacrolimus—Pain—Methotrexate—esophageal cancer	5.36e-05	0.000419	CcSEcCtD
Tacrolimus—Vomiting—Capecitabine—esophageal cancer	5.35e-05	0.000419	CcSEcCtD
Tacrolimus—Rash—Capecitabine—esophageal cancer	5.31e-05	0.000415	CcSEcCtD
Tacrolimus—Dermatitis—Capecitabine—esophageal cancer	5.3e-05	0.000415	CcSEcCtD
Tacrolimus—Headache—Capecitabine—esophageal cancer	5.27e-05	0.000413	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—esophageal cancer	5.16e-05	0.000404	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—esophageal cancer	5.12e-05	0.000401	CcSEcCtD
Tacrolimus—Nausea—Capecitabine—esophageal cancer	5e-05	0.000391	CcSEcCtD
Tacrolimus—Urticaria—Methotrexate—esophageal cancer	4.98e-05	0.00039	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—esophageal cancer	4.95e-05	0.000388	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—esophageal cancer	4.95e-05	0.000388	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—esophageal cancer	4.61e-05	0.000361	CcSEcCtD
Tacrolimus—Asthenia—Methotrexate—esophageal cancer	4.49e-05	0.000352	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—esophageal cancer	4.43e-05	0.000347	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—esophageal cancer	4.29e-05	0.000336	CcSEcCtD
Tacrolimus—Dizziness—Methotrexate—esophageal cancer	4.14e-05	0.000324	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—esophageal cancer	3.98e-05	0.000312	CcSEcCtD
Tacrolimus—Rash—Methotrexate—esophageal cancer	3.95e-05	0.000309	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—esophageal cancer	3.95e-05	0.000309	CcSEcCtD
Tacrolimus—Headache—Methotrexate—esophageal cancer	3.92e-05	0.000307	CcSEcCtD
Tacrolimus—Nausea—Methotrexate—esophageal cancer	3.72e-05	0.000291	CcSEcCtD
Tacrolimus—ALB—Metabolism—ADH7—esophageal cancer	1.5e-05	0.000156	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NOS3—esophageal cancer	1.5e-05	0.000155	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CTNNA1—esophageal cancer	1.49e-05	0.000155	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.49e-05	0.000155	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALDH2—esophageal cancer	1.49e-05	0.000155	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFBR2—esophageal cancer	1.49e-05	0.000154	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL2—esophageal cancer	1.49e-05	0.000154	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.49e-05	0.000154	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—EGFR—esophageal cancer	1.49e-05	0.000154	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—ABL1—esophageal cancer	1.48e-05	0.000153	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EP300—esophageal cancer	1.47e-05	0.000152	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—ERBB2—esophageal cancer	1.47e-05	0.000152	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TYMP—esophageal cancer	1.46e-05	0.000152	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HIF1A—esophageal cancer	1.43e-05	0.000149	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP26A1—esophageal cancer	1.42e-05	0.000147	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTT1—esophageal cancer	1.42e-05	0.000147	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CA2—esophageal cancer	1.42e-05	0.000147	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SMAD4—esophageal cancer	1.41e-05	0.000146	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ERBB2—esophageal cancer	1.41e-05	0.000146	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP2A6—esophageal cancer	1.4e-05	0.000145	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ERBB2—esophageal cancer	1.4e-05	0.000145	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PSME2—esophageal cancer	1.39e-05	0.000144	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PSME1—esophageal cancer	1.39e-05	0.000144	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALOX15—esophageal cancer	1.39e-05	0.000144	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ANXA1—esophageal cancer	1.38e-05	0.000143	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KDR—esophageal cancer	1.37e-05	0.000142	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—esophageal cancer	1.37e-05	0.000142	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EGFR—esophageal cancer	1.36e-05	0.000141	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NOS3—esophageal cancer	1.35e-05	0.00014	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.35e-05	0.00014	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SST—esophageal cancer	1.34e-05	0.000139	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ENO1—esophageal cancer	1.33e-05	0.000138	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS1—esophageal cancer	1.33e-05	0.000138	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TPI1—esophageal cancer	1.32e-05	0.000137	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTO1—esophageal cancer	1.32e-05	0.000137	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ADH1B—esophageal cancer	1.32e-05	0.000137	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PLCE1—esophageal cancer	1.32e-05	0.000136	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ADH7—esophageal cancer	1.32e-05	0.000136	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PSME2—esophageal cancer	1.31e-05	0.000136	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PSME1—esophageal cancer	1.31e-05	0.000136	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOTCH3—esophageal cancer	1.31e-05	0.000136	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GHRL—esophageal cancer	1.31e-05	0.000136	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.31e-05	0.000135	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NOTCH1—esophageal cancer	1.29e-05	0.000134	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.29e-05	0.000134	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—PIK3CA—esophageal cancer	1.29e-05	0.000134	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FBXW7—esophageal cancer	1.29e-05	0.000134	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MYC—esophageal cancer	1.28e-05	0.000133	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALDOB—esophageal cancer	1.27e-05	0.000131	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ERBB2—esophageal cancer	1.27e-05	0.000131	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TYMP—esophageal cancer	1.26e-05	0.000131	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EGFR—esophageal cancer	1.25e-05	0.00013	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CDKN1A—esophageal cancer	1.25e-05	0.00013	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.24e-05	0.000129	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	1.24e-05	0.000128	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP26A1—esophageal cancer	1.23e-05	0.000127	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GAPDH—esophageal cancer	1.22e-05	0.000126	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CRABP1—esophageal cancer	1.21e-05	0.000125	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CDKN1A—esophageal cancer	1.2e-05	0.000125	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CDKN1A—esophageal cancer	1.2e-05	0.000124	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ALOX15—esophageal cancer	1.19e-05	0.000124	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TLR4—esophageal cancer	1.19e-05	0.000124	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EP300—esophageal cancer	1.19e-05	0.000124	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PIK3CA—esophageal cancer	1.18e-05	0.000122	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOTCH2—esophageal cancer	1.17e-05	0.000122	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CREBBP—esophageal cancer	1.17e-05	0.000121	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ADH1B—esophageal cancer	1.15e-05	0.00012	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HIF1A—esophageal cancer	1.15e-05	0.000119	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GNG7—esophageal cancer	1.15e-05	0.000119	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EP300—esophageal cancer	1.14e-05	0.000118	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TPI1—esophageal cancer	1.14e-05	0.000118	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTO1—esophageal cancer	1.14e-05	0.000118	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP1B1—esophageal cancer	1.13e-05	0.000117	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.13e-05	0.000117	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.12e-05	0.000116	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.12e-05	0.000116	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCND1—esophageal cancer	1.12e-05	0.000116	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TYMP—esophageal cancer	1.1e-05	0.000114	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ALDOB—esophageal cancer	1.09e-05	0.000113	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PIK3CA—esophageal cancer	1.09e-05	0.000113	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.08e-05	0.000112	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CDKN1A—esophageal cancer	1.08e-05	0.000112	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALDH2—esophageal cancer	1.08e-05	0.000112	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.07e-05	0.000111	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NOS2—esophageal cancer	1.06e-05	0.00011	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP19A1—esophageal cancer	1.06e-05	0.00011	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.06e-05	0.00011	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GAPDH—esophageal cancer	1.05e-05	0.000109	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NOS3—esophageal cancer	1.05e-05	0.000109	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOS2—esophageal cancer	1.05e-05	0.000109	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALOX15—esophageal cancer	1.05e-05	0.000108	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFBR2—esophageal cancer	1.04e-05	0.000108	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CRABP1—esophageal cancer	1.04e-05	0.000108	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOTCH1—esophageal cancer	1.04e-05	0.000108	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EP300—esophageal cancer	1.03e-05	0.000107	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTT1—esophageal cancer	1.03e-05	0.000106	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CASP8—esophageal cancer	1.02e-05	0.000106	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CREBBP—esophageal cancer	1.02e-05	0.000106	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—esophageal cancer	1.02e-05	0.000105	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP2A6—esophageal cancer	1.01e-05	0.000105	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTO1—esophageal cancer	9.98e-06	0.000103	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TPI1—esophageal cancer	9.98e-06	0.000103	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MYC—esophageal cancer	9.93e-06	0.000103	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GNG7—esophageal cancer	9.91e-06	0.000103	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SMAD4—esophageal cancer	9.86e-06	0.000102	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ERBB2—esophageal cancer	9.82e-06	0.000102	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—esophageal cancer	9.76e-06	0.000101	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—esophageal cancer	9.72e-06	0.000101	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—HMOX1—esophageal cancer	9.7e-06	0.000101	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ENO1—esophageal cancer	9.61e-06	9.96e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS1—esophageal cancer	9.61e-06	9.96e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALDOB—esophageal cancer	9.57e-06	9.92e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—CREBBP—esophageal cancer	9.55e-06	9.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CA1—esophageal cancer	9.54e-06	9.89e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.54e-06	9.89e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PSME2—esophageal cancer	9.47e-06	9.81e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PSME1—esophageal cancer	9.47e-06	9.81e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CREBBP—esophageal cancer	9.41e-06	9.75e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	9.34e-06	9.68e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ABCB1—esophageal cancer	9.31e-06	9.65e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ALDH2—esophageal cancer	9.29e-06	9.62e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GAPDH—esophageal cancer	9.21e-06	9.55e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	9.19e-06	9.53e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CRABP1—esophageal cancer	9.13e-06	9.46e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—esophageal cancer	8.97e-06	9.3e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	8.9e-06	9.22e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTT1—esophageal cancer	8.83e-06	9.15e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PIK3CA—esophageal cancer	8.82e-06	9.14e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—BCL2—esophageal cancer	8.79e-06	9.11e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—esophageal cancer	8.77e-06	9.09e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP2A6—esophageal cancer	8.73e-06	9.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CA2—esophageal cancer	8.73e-06	9.04e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.7e-06	9.01e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GNG7—esophageal cancer	8.68e-06	9e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—esophageal cancer	8.67e-06	8.99e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NOS3—esophageal cancer	8.55e-06	8.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ERBB2—esophageal cancer	8.54e-06	8.85e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PIK3CA—esophageal cancer	8.47e-06	8.78e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PIK3CA—esophageal cancer	8.43e-06	8.74e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOS3—esophageal cancer	8.43e-06	8.73e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CDKN1A—esophageal cancer	8.39e-06	8.69e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS1—esophageal cancer	8.28e-06	8.58e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ENO1—esophageal cancer	8.28e-06	8.58e-05	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	8.27e-06	8.57e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP1B1—esophageal cancer	8.17e-06	8.47e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PSME1—esophageal cancer	8.16e-06	8.45e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PSME2—esophageal cancer	8.16e-06	8.45e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALDH2—esophageal cancer	8.14e-06	8.43e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLCE1—esophageal cancer	8.11e-06	8.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ADH7—esophageal cancer	8.11e-06	8.41e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HIF1A—esophageal cancer	8.07e-06	8.36e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EP300—esophageal cancer	7.98e-06	8.27e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERBB2—esophageal cancer	7.88e-06	8.17e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTT1—esophageal cancer	7.74e-06	8.02e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KDR—esophageal cancer	7.72e-06	8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—esophageal cancer	7.71e-06	7.99e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP19A1—esophageal cancer	7.68e-06	7.96e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP2A6—esophageal cancer	7.65e-06	7.93e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—esophageal cancer	7.62e-06	7.89e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—esophageal cancer	7.37e-06	7.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1A—esophageal cancer	7.3e-06	7.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOTCH1—esophageal cancer	7.27e-06	7.53e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS1—esophageal cancer	7.25e-06	7.52e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ENO1—esophageal cancer	7.25e-06	7.52e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	7.25e-06	7.51e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PSME1—esophageal cancer	7.15e-06	7.41e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PSME2—esophageal cancer	7.15e-06	7.41e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.12e-06	7.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ADH1B—esophageal cancer	7.12e-06	7.37e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP1B1—esophageal cancer	7.04e-06	7.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HMOX1—esophageal cancer	7.01e-06	7.27e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—esophageal cancer	6.96e-06	7.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EP300—esophageal cancer	6.94e-06	7.2e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—esophageal cancer	6.8e-06	7.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TYMP—esophageal cancer	6.8e-06	7.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1A—esophageal cancer	6.74e-06	6.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ABCB1—esophageal cancer	6.73e-06	6.97e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP19A1—esophageal cancer	6.62e-06	6.86e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.62e-06	6.85e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CREBBP—esophageal cancer	6.59e-06	6.83e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EP300—esophageal cancer	6.51e-06	6.74e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.45e-06	6.68e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EP300—esophageal cancer	6.41e-06	6.64e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CREBBP—esophageal cancer	6.22e-06	6.45e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP1B1—esophageal cancer	6.17e-06	6.39e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.15e-06	6.37e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TPI1—esophageal cancer	6.15e-06	6.37e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HMOX1—esophageal cancer	6.04e-06	6.26e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.92e-06	6.14e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—esophageal cancer	5.92e-06	6.13e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—esophageal cancer	5.91e-06	6.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOS3—esophageal cancer	5.9e-06	6.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.9e-06	6.11e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP19A1—esophageal cancer	5.8e-06	6.01e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ABCB1—esophageal cancer	5.8e-06	6.01e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—esophageal cancer	5.71e-06	5.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.68e-06	5.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.62e-06	5.83e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—esophageal cancer	5.59e-06	5.79e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NOS3—esophageal cancer	5.57e-06	5.77e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB2—esophageal cancer	5.52e-06	5.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—esophageal cancer	5.46e-06	5.66e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNG7—esophageal cancer	5.35e-06	5.54e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HMOX1—esophageal cancer	5.29e-06	5.48e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—esophageal cancer	5.14e-06	5.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—esophageal cancer	5.1e-06	5.28e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.01e-06	5.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—esophageal cancer	4.88e-06	5.05e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—esophageal cancer	4.81e-06	4.99e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.77e-06	4.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—esophageal cancer	4.74e-06	4.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1A—esophageal cancer	4.72e-06	4.89e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.71e-06	4.88e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—esophageal cancer	4.66e-06	4.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CREBBP—esophageal cancer	4.5e-06	4.66e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EP300—esophageal cancer	4.49e-06	4.65e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ENO1—esophageal cancer	4.47e-06	4.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.47e-06	4.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PSME2—esophageal cancer	4.4e-06	4.56e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PSME1—esophageal cancer	4.4e-06	4.56e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.38e-06	4.54e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—EP300—esophageal cancer	4.24e-06	4.39e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NOS3—esophageal cancer	4.03e-06	4.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—esophageal cancer	3.91e-06	4.05e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CREBBP—esophageal cancer	3.87e-06	4.01e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—esophageal cancer	3.83e-06	3.97e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.8e-06	3.94e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—esophageal cancer	3.68e-06	3.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.57e-06	3.7e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NOS3—esophageal cancer	3.47e-06	3.59e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CREBBP—esophageal cancer	3.39e-06	3.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—esophageal cancer	3.32e-06	3.44e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.26e-06	3.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—esophageal cancer	3.21e-06	3.33e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—esophageal cancer	3.17e-06	3.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—esophageal cancer	3.13e-06	3.25e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.13e-06	3.24e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—EP300—esophageal cancer	3.06e-06	3.17e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NOS3—esophageal cancer	3.04e-06	3.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—esophageal cancer	2.78e-06	2.88e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—EP300—esophageal cancer	2.64e-06	2.73e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—EP300—esophageal cancer	2.31e-06	2.4e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—esophageal cancer	2.27e-06	2.35e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.09e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—esophageal cancer	1.95e-06	2.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NOS3—esophageal cancer	1.87e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.71e-06	1.77e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.71e-06	1.77e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—EP300—esophageal cancer	1.42e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.05e-06	1.09e-05	CbGpPWpGaD
